Vii Associates Lpblair Jame... Net Worth

The estimated Net Worth of Vii Associates Lpblair Jame... is at least $65.5 Tysiąc dollars as of 26 May 2016. Vii Jame owns over 5,880 units of Obalon Therapeutics Inc stock worth over $28,609 and over the last 9 years Vii sold OBLN stock worth over $36,846.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Vii Jame OBLN stock SEC Form 4 insiders trading

Vii has made over 5 trades of the Obalon Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Vii sold 5,880 units of OBLN stock worth $27,636 on 26 May 2016.

The largest trade Vii's ever made was selling 5,880 units of Obalon Therapeutics Inc stock on 26 May 2016 worth over $27,636. On average, Vii trades about 1,270 units every 8 days since 2016. As of 26 May 2016 Vii still owns at least 10,328 units of Obalon Therapeutics Inc stock.

You can see the complete history of Vii Jame stock trades at the bottom of the page.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... oraz David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.

What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Complete history of Vii Jame stock trades at Evoke Pharma Inc i Obalon Therapeutics Inc

Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Kelly Huang Ph.D.,
  Consultant
• Andrew Rasdal,
  Chairman of the Board, President, Chief Executive Officer
• Andrew P. Rasdal,
  CEO, Pres & Director
• Sharon Stevenson,
  Independent Director
• Lesley Howe,
  Independent Director
• Douglas Fisher,
  Independent Director
• Raymond Dittamore,
  Independent Director
• William Plovanic,
  Director
• Robert MacDonald,
  Chief Retail Officer
• Donald Young,
  Vice President of Quality Assurance
• Todd Wood,
  Vice President - Global Sales
• Lisa Metzner,
  Vice President of Marketing
• Matthew Norwood,
  Vice President of Sales
• Steve Johnson,
  Vice President - Operations
• Nooshin Hussainy,
  Chief Financial Officer
• Nooshin Hussainy,
  CFO & Sec.
• Kim P. Kamdar,
  
• Erin Morisey,
  VP Strategic Partnerships
• Partners X Lp Inter West Ma...,
  
• David Moatazedi,
  
• Vii Associates Lpblair Jame...,
  
• Parters Vii L Pblair James ...,
  
• Amy Vanden Berg,
  Chief Clinical & Reg Officer
• Kelly Huang,
  Pres & Chief Executive Officer
• Robert H Jr Mondore,
  VP of Operations
• Jonah Shacknai,
  
• Partners X Lp Inter West Ma...,
  
• Daina Schmidt,
  Vice President of Marketing
• Mark Brister,
  Chief Technology Officer